Wave Life Sciences Ltd. (NASDAQ: WVE) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. Given the unique versatility of its chemistry platform, Wave's pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.